All In Biotech

Drug Trial Radar · NCT05031780

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

286

Actual

Start

Feb 11, 2022

Primary completion

Oct 30, 2025

Study completion Feb 2030

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.

Conditions

  • Sickle Cell Disease

Interventions

  • MitapivatDrug

    Mitapivat tablets

  • Mitapivat-matching placeboOther

    Placebo to match 50 mg or 100 mg tablets

  • Mitapivat-matching placeboOther

    Placebo to match 100 mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Percentage of Participants With Hemoglobin (Hb) ResponseTime frame: Week 12
  2. Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)Time frame: Up to Week 12
  3. Phase 3: Percentage of Participants With Hb ResponseTime frame: Week 52
  4. Phase 3: Annualized Rate of Sickle Cell Pain Crises (SCPCs)Time frame: Up to Week 52

Locations

91 sites in 16 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • UCLA Health

    Los Angeles, California

  • Children's Hospital Oakland

    Oakland, California

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Children's National Hospital

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Sylvester Comprehensive Cancer Center-Miami

    Miami, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • Riley Hospital For Children

    Indianapolis, Indiana

  • LSU Health Sciences Center - Shreveport

    Shreveport, Louisiana

  • National Heart Lung and Blood Institute

    Bethesda, Maryland

  • Kaiser Permanente - Largo Medical Center

    Largo, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Boston Medical Center & Boston University School of Medicine

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Southern Specialty Clinic

    Flowood, Mississippi

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Cure 4 The Kids Foundation, A Division of Roseman University of Health Sciences

    Las Vegas, Nevada

  • East Carolina University - Brody School of Medicine

    Greenville, North Carolina

  • Penn Medicine - University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania

  • Lifespan at Rhode Island Hospital

    Providence, Rhode Island

  • University of Texas Health Science Center of Houston

    Houston, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Seattle Cancer Care Alliance, University of Washington

    Seattle, Washington

  • ZAS Cadix

    Antwerp, Belgium

  • CHR de la Citadelle

    Liège, Belgium

  • Clinique CHC MontLégia

    Liège, Belgium

  • Hôpital Erasme

    Anderlecht, Brussels Capital, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Brussels Capital, Belgium

  • HEMORIO Instituto Nacional de Hematologia

    Rio de Janeiro, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo

    São Paulo, Brazil

  • Multihemo Servicos Medicos S/A

    Recife, Pernambuco, Brazil

  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas da Unicamp

    Campinas, São Paulo, Brazil

  • Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

    Ribeirão Preto, São Paulo, Brazil

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.